Literature DB >> 28427100

Dystrophinopathies and Limb-Girdle Muscular Dystrophies.

Joana Domingos1, Anna Sarkozy1, Mariacristina Scoto1, Francesco Muntoni1.   

Abstract

Muscular dystrophies are a heterogeneous group of inherited diseases. The natural history of these disorders along with their management have changed mainly due to a better understanding of their pathophysiology, the evolution of standards of care, and new treatment options. Dystrophinopathies include both Duchenne's and Becker's muscular dystrophies, but in reality they are a spectrum of muscle diseases caused by mutations in the gene that encodes the protein dystrophin. Duchenne's muscular dystrophy is the most common form of inherited muscle disease of childhood. The current standards of care considerably prolong independent ambulation and survival. Several therapeutic options either aiming at substituting/correcting the primary protein defect or limiting the progression of the dystrophic process are currently being explored in clinical trials.Limb-girdle muscular dystrophies (LGMDs) are rare and heterogeneous conditions, characterized by weakness and wasting of the pelvic and shoulder girdle muscles. Originally classified into dominant and recessive, > 30 genetic forms of LGMDs are currently recognized. Further understanding of the pathogenic mechanisms of LGMD will help identifying novel therapeutic approaches that can be tested in clinical trials. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28427100     DOI: 10.1055/s-0037-1601860

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  7 in total

Review 1.  The Prognosis of Arthrofibroses: Prevalence, Clinical Shortcomings, and Future Prospects.

Authors:  William A Blessing; Amanda K Williamson; Jack R Kirsch; Mark W Grinstaff
Journal:  Trends Pharmacol Sci       Date:  2021-03-29       Impact factor: 14.819

Review 2.  Genetic and Clinical Advances of Congenital Muscular Dystrophy.

Authors:  Xiao-Na Fu; Hui Xiong
Journal:  Chin Med J (Engl)       Date:  2017-11-05       Impact factor: 2.628

Review 3.  Anesthetic management of a patient with limb-girdle muscular dystrophy 2B:CARE-compliant case report and literature review.

Authors:  X Q Cao; K Joypaul; F Cao; L L Gui; J T Hu; W Mei
Journal:  BMC Anesthesiol       Date:  2019-08-17       Impact factor: 2.217

4.  User-centred assistive SystEm for arm Functions in neUromuscuLar subjects (USEFUL): a randomized controlled study.

Authors:  Valeria Longatelli; Alberto Antonietti; Emilia Biffi; Eleonora Diella; Maria Grazia D'Angelo; Mauro Rossini; Franco Molteni; Marco Bocciolone; Alessandra Pedrocchi; Marta Gandolla
Journal:  J Neuroeng Rehabil       Date:  2021-01-06       Impact factor: 4.262

5.  Anti-latent TGFβ binding protein 4 antibody improves muscle function and reduces muscle fibrosis in muscular dystrophy.

Authors:  Alexis R Demonbreun; Katherine S Fallon; Claire C Oosterbaan; Lauren A Vaught; Nina L Reiser; Elena Bogdanovic; Matthew P Velez; Isabella M Salamone; Patrick G T Page; Michele Hadhazy; Mattia Quattrocelli; David Y Barefield; Lauren D Wood; J Patrick Gonzalez; Carl Morris; Elizabeth M McNally
Journal:  Sci Transl Med       Date:  2021-09-08       Impact factor: 19.319

Review 6.  Diagnosis of Cardiac Abnormalities in Muscular Dystrophies.

Authors:  Elisabeta Bădilă; Iulia Ioana Lungu; Alexandru Mihai Grumezescu; Alexandru Scafa Udriște
Journal:  Medicina (Kaunas)       Date:  2021-05-12       Impact factor: 2.430

7.  Platelet Derived Growth Factor-AA Correlates With Muscle Function Tests and Quantitative Muscle Magnetic Resonance in Dystrophinopathies.

Authors:  Alicia Alonso-Jiménez; Esther Fernández-Simón; Daniel Natera-de Benito; Carlos Ortez; Carme García; Elena Montiel; Izaskun Belmonte; Irene Pedrosa; Sonia Segovia; Patricia Piñol-Jurado; Ana Carrasco-Rozas; Xavier Suárez-Calvet; Cecilia Jimenez-Mallebrera; Andrés Nascimento; Jaume Llauger; Claudia Nuñez-Peralta; Paula Montesinos; Jorge Alonso-Pérez; Eduard Gallardo; Isabel Illa; Jordi Díaz-Manera
Journal:  Front Neurol       Date:  2021-06-11       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.